What's The Point Of Nobody Caring About Personalized Depression Treatment > 자유게시판

Personalized Depression Treatment

For many suffering from depression, traditional therapies and medications are not effective. The individual approach to treatment could be the answer.

Cue is a digital intervention platform that translates passively acquired normal sensor data from smartphones into customized micro-interventions to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to identify their feature predictors and reveal distinct features that deterministically change mood with time.

Predictors of Mood

Depression is among the leading causes of mental illness.1 Yet, only half of people suffering from the disorder receive treatment1. To improve the outcomes, clinicians need to be able to identify and treat patients with the highest probability of responding to certain treatments.

Personalized depression treatment can help. By using sensors on mobile phones, an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from the treatments they receive. With two grants awarded totaling over $10 million, they will make use of these techniques to determine the biological and behavioral factors that determine the response to antidepressant medication and psychotherapy.

The majority of research conducted to date has focused on sociodemographic and clinical characteristics. These include demographics such as age, gender and education, and clinical characteristics like symptom severity and comorbidities as well as biological markers.

A few studies have utilized longitudinal data to determine mood among individuals. Few studies also take into consideration the fact that mood can differ significantly between individuals. Therefore, it is critical to develop methods that allow for the determination of different mood predictors for each person and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can detect distinct patterns of behavior and emotions that are different between people.

The team also developed an algorithm for machine learning to model dynamic predictors for each person's depression mood. The algorithm integrates the individual differences to create an individual "digital genotype" for each participant.

The digital phenotype was associated with CAT-DI scores, a psychometrically validated severity scale for symptom severity. The correlation was weak, however (Pearson r = 0,08; P-value adjusted for BH = 3.55 x 10 03) and varied significantly among individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1, but it is often untreated and not diagnosed. Depression disorders are rarely treated because of the stigma associated with them, as well as the lack of effective interventions.

To assist in individualized treatment, it is essential to identify predictors of symptoms. The current methods for predicting symptoms rely heavily on clinical interviews, which aren't reliable and only reveal a few characteristics that are associated with depression.

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous digital behavioral phenotypes gathered from smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes permit continuous, high-resolution measurements as well as capture a wide variety of unique behaviors and activity patterns that are difficult to document through interviews.

The study enrolled University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA hormonal depression treatment Grand Challenge. Participants were referred to online support or in-person clinical treatment according to the severity of their depression. Those with a CAT-DI score of 35 65 were given online support with a coach and those with scores of 75 patients were referred for in-person psychotherapy.

At the beginning, participants answered an array of questions regarding their personal demographics and psychosocial characteristics. The questions asked included age, sex and education and financial status, marital status and whether they were divorced or not, the frequency of suicidal thoughts, intent or attempts, and how often they drank. The CAT-DI was used to assess the severity of depression symptoms on a scale of 0-100. The CAT DI assessment was carried out every two weeks for those who received online support and weekly for those who received in-person assistance.

Predictors of Treatment Response

Research is focusing on personalized treatment for depression. Many studies are focused on finding predictors that can aid clinicians in identifying the most effective medications for each person. Pharmacogenetics, in particular, identifies genetic variations that determine the way that our bodies process drugs. This lets doctors select the medication that are likely to be the most effective for each patient, while minimizing the amount of time and effort required for trial-and error treatments and eliminating any adverse effects.

Another promising approach is building models of prediction using a variety of data sources, including clinical information and neural imaging data. These models can be used to determine which variables are most predictive of a particular outcome, such as whether a medication will improve symptoms or mood. These models can be used to determine a patient's response to an existing treatment and help doctors maximize the effectiveness of their current treatment.

A new era of research employs machine learning techniques, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to blend the effects of several variables to improve predictive accuracy. These models have proven to be useful for the prediction of treatment outcomes like the response to antidepressants. These methods are becoming more popular in psychiatry, and are likely to become the norm in the future treatment.

Research into the underlying causes of depression continues, in addition to predictive models based on ML. Recent findings suggest that the disorder is connected with neurodegeneration in particular circuits. This suggests that individual depression treatment will be built around targeted therapies that target these circuits in order to restore normal function.

One method of doing this is by using internet-based programs which can offer an personalized and customized experience for patients. A study showed that a web-based program improved symptoms and provided a better quality of life for MDD patients. A controlled study that was randomized to a customized treatment for psychotic depression treatment found that a significant number of patients experienced sustained improvement as well as fewer side effects.

Predictors of adverse effects

A major challenge in personalized depression treatment involves identifying and predicting the antidepressant medications that will have minimal or no side effects. Many patients are prescribed various medications before settling on a treatment that is effective and tolerated. Pharmacogenetics offers a fresh and exciting method to choose antidepressant medications that is more efficient and targeted.

There are a variety of variables that can be used to determine the antidepressant that should be prescribed, including gene variations, patient phenotypes such as gender or ethnicity, and comorbidities. To identify the most effective treatment for depression reliable and accurate predictors for a specific treatment, randomized controlled trials with larger samples will be required. This is because it could be more difficult to detect the effects of moderators or interactions in trials that comprise only one episode per participant instead of multiple episodes spread over a period of time.

In addition the prediction of a patient's response will likely require information on the comorbidities, symptoms profiles and the patient's personal perception of the effectiveness and tolerability. At present, only a few easily identifiable sociodemographic and clinical variables appear to be reliable in predicting response to MDD, such as gender, age, race/ethnicity and SES, BMI, the presence of alexithymia, and the severity of depression symptoms.

The application of pharmacogenetics to depression treatment is still in its early stages and there are many obstacles to overcome. First is a thorough understanding of the genetic mechanisms is required, as is an understanding of what is a reliable indicator of treatment response. Additionally, ethical issues, such as privacy and the ethical use of personal genetic information must be carefully considered. Pharmacogenetics could be able to, over the long term, reduce stigma surrounding mental health treatment and improve the outcomes of treatment. Like any other psychiatric treatment, it is important to take your time and carefully implement the plan. For now, the best method is to provide patients with an array of effective depression treatment types medications and encourage them to speak freely with their doctors about their concerns and experiences.